|MDACC Study No:||2012-0205 (clinicaltrials.gov NCT No: NCT01575925)|
|Title:||A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Dexamethasone; Pomalidomide|
|Study Description:||The goal of this clinical research study is to learn the highest tolerated dose |
of pomalidomide that can be given in combination with dexamethasone in relapsed
or refractory MM. In addition, researchers will look at the drug dynamics of
pomalidomide in patients with kidney failure. The safety of this drug
combination will also be tested.
Pomalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.